When Fran Visco was diagnosed with breast cancer at age 39 in 1987, she feared she wouldn’t live past 40 or see her infant son grow up. On Wednesday, she celebrated her 77th birthday. Her son — now a ...
The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...
In addition to using gemcitabine and the natural killer cells that are TGF-β imprinted, we also are combining an anti-GD2 antibody called naxitamab that's provided by Y-mAbs. Naxitamab, as I said, is ...
On the latest episode of the Joe Rogan Experience, actor Mel Gibson left the veteran podcaster shocked by the controversial ...
New study successfully made CTC-derived organoids from breast cancer patients' blood samples to investigate cell survival and ...
Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...
Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer ...
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...
NICE's endorsement of olaparib, produced by AstraZeneca, marks a crucial step forward in the treatment of breast cancer. This ...